The availability of small molecule compounds (such as selumetinib and imatinib) that target RAS signaling implied in the pathogenesis of plexiform neurofibromas has led to multiple clinical trials, and FDA has approved Koselugo (selumetinib) for the treatment of pediatric patients with NF1 mutations.42 Here, NF1 is linked to plexiform neurofibroma.